FORT MYERS, Fla., Nov. 2 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. announced today that its third quarter financial statements were still being reviewed by its auditors and, as a result, it does not expect to release its full Q3 FY 2007 financial results until the week of November 12th. Given this delay, however, the Company is releasing its Q3 07 revenue-related metrics now, which are not expected to change. The table below includes the key revenue metrics for the three and nine month periods ended September 30, 2007 as well as the preliminary revenue figures for these periods.
The Company also announced today that President and Chief Scientific Officer, Bob Gasparini, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference being held from November 5-7, 2007 at the New York Palace Hotel in New York City. The conference will showcase over 350 small and microcap public life sciences and biotech companies. Gasparini and other senior executives of attending companies will make presentations to portfolio managers and analysts on their business strategy and outlook. One- on-one meetings with interested parties will also be arranged during the three-day conference. NeoGenomics is scheduled to present on Monday November 5th at 2:40 PM. A webcast of the presentation can be accessed at http://www.wsw.com/webcast/rrshq12/ngnm.ob. A PowerPoint presentation and a link to the webcast can also be accessed through the investor relations section of the NeoGenomics website at http://www.neogenomics.org at the time of the conference. The webcast will be available for three months.
Robert Gasparini, the Company's President and Chief Scientific Officer, stated, "While we realize it is somewhat unusual to release our key revenue- related metrics prior to our full financial results, we felt it was important to get at least some information out into the public before presenting at a major investor conference. Although we will still be in a net loss position for Q3 07, we are quite pleased with our 95% year over year revenue growth versus Q3 06 and we are looking forward to sharing our full results with investors the week of November 12th. We are also delighted with our 33% sequential increase in revenues from Q2 07 and believe that we are now starting to reach the inflection point in our growth that we have been expecting. Indeed we expect that our net loss for Q3, when finalized, will be substantially reduced from the net loss we recorded in Q2 07."
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org.
Interested parties can also access additional investor relations material from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm/ or from Hawk Associates at http://www.hawkassociates.com. An investment profile about NeoGenomics may be found at http://www.hawkassociates.com/ngnmprofile.aspx.
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC. NeoGenomics, Inc.
CONTACT: Steven C. Jones, Director of Investor Relations of NeoGenomics,
Inc., +1-239-325-2001, sjones@neogenomics.org; or Frank N. Hawkins or Julie
Marshall, both of Hawk and Associates, Inc., +1-305-451-1888,
info@hawkassociates.com
Web site: http://www.neogenomics.org/
http://www.wsw.com/webcast/rrshq12/ngnm.ob/
http://www.hawkassociates.com/ngnmprofile.aspx/
http://www.americanmicrocapinstitute.com/ngnm/
http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf21/
